PT - JOURNAL ARTICLE AU - Luís A. Vale-Silva AU - Karl Rohr TI - MultiSurv: Long-term cancer survival prediction using multimodal deep learning AID - 10.1101/2020.08.06.20169698 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.06.20169698 4099 - http://medrxiv.org/content/early/2020/08/07/2020.08.06.20169698.short 4100 - http://medrxiv.org/content/early/2020/08/07/2020.08.06.20169698.full AB - The age of precision medicine demands powerful computational techniques to handle high-dimensional patient data. We present MultiSurv, a multimodal deep learning method for long-term pan-cancer survival prediction. MultiSurv is composed of three main modules. A feature representation module includes a dedicated submodel for each input data modality. A data fusion layer aggregates the multimodal representations. Finally, a prediction submodel yields conditional survival probabilities for a predefined set of follow-up time intervals. We trained MultiSurv on clinical, imaging, and four different high-dimensional omics data modalities from patients diagnosed with one of 33 different cancer types. We evaluated unimodal input configurations against several previous methods and different multimodal data combinations. MultiSurv achieved the best results according to different time-dependent metrics and delivered highly accurate long-term patient survival curves. The best performance was obtained when combining clinical information with either gene expression or DNA methylation data, depending on the evaluation metric. Additionally, MultiSurv can handle missing data, including missing values and complete data modalitites. Interestingly, for unimodal data we found that simpler modeling approaches, including the classical Cox proportional hazards method, can achieve results rivaling those of more complex methods for certain data modalities. We also show how the learned feature representations of MultiSurv can be used to visualize relationships between cancer types and individual patients, after embedding into a low-dimensional space.Competing Interest StatementThe authors have declared no competing interest.Funding StatementL.A.V.S. was supported by an individual fellowship from the Chica and Heinz Schaller Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All necessary patient/participant consent and necessary approvals have been obtained to make the data publicly available. Data used in this study is not individually identifiable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this work are from The Cancer Genome Atlas (TCGA) program. The used datasets are available publicly from the National Cancer Institute (NCI) Genomic Data Commons (GDC) information system, accessible at the GDC Data Portal. https://portal.gdc.cancer.gov/